Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells

Dubash, TD; Bardia, A; Chirn, B; Reeves, BA; LiCausi, JA; Burr, R; Wittner, BS; Rai, S; Patel, H; Bihani, T; Arlt, H; Bidard, FC; Kaklamani, VG; Aftimos, P; Cortés, J; Scartoni, S; Fiascarelli, A; Binaschi, M; Habboubi, N; Iafrate, AJ; Toner, M; Haber, DA; Maheswaran, S

Haber, DA; Maheswaran, S (通讯作者)，Massachusetts Gen Hosp Canc Ctr, Boston, MA 02114 USA.;Haber, DA; Maheswaran, S (通讯作者)，Harvard Med Sch, Boston, MA 02114 USA.;Haber, DA (通讯作者)，Howard Hughes Med Inst, Bethesda, MD 20810 USA.

BREAST CANCER RESEARCH AND TREATMENT, 2023; 201 (1): 43

Abstract

PurposeMetastatic hormone receptor-positive (HR+) breast cancer initially responds to serial courses of endocrine therapy, but ultimately becomes refr......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索